TRIMAZOSIN

Trimazosin is an alpha1 adrenergic blocker used for hypertension and urinary obstruction. It relaxes smooth muscle and lowers blood pressure. Side effects include dizziness, hypotension, nasal congestion, and fatigue. Only GMP materials will be supplied, logistics all according to GDP.

SKU: 3cc3ff821b7b Category: Tag:

Product Description


Mechanism of Action

TRIMAZOSIN demonstrates multilayer biochemical influence across signalling hierarchies, catalyticdomain regulation, mitochondrialnetwork energetics, iongradient stability, membrane electrochemistry, redox equilibrium and transcriptionfactor axis alignment. Its molecular topology enables interaction with catalytic residues, allosteric nodes, hydrophobic receptor microdomains, transmembrane helices, redoxbuffer matrices and cytoskeletal scaffolds, resulting in widespectrum modulation across metabolic, structural, electrophysiological and genomic systems.

Mechanistically, TRIMAZOSIN may remodel phosphorylation flux across MAPK/ERK/JNK/p38 pathways, reshape PI3KAKT survival topology, modify Gprotein coupling dynamics, reorganise Ca²⁺ signalling microdomains, influence IP/DAG cascade geometry and adjust cAMPPKA amplitude distributions. Mitochondrial impacts include ETCcomplex rebalancing, ATP/ADP turnover pattern shifts, ROSthreshold displacement, membranepotential polarity modulation and ERmitochondrial stresscrosstalk regulation.

Advanced

  • Kinomescale interference mapping and catalyticcascade simulation
  • Highresolution docking and conformationaltransition modelling
  • UPR/ERstress, autophagymitophagy and organellenetwork integration research
  • Multiomics regulatory reconstruction (RNAseq, phosphoproteomics, metabolomics, proteomics)
  • Cytoskeletal tensionmapping and polymerturnover analysis
  • Cellfate simulations (apoptosis, necroptosis, ferroptosis, parthanatos)
  • Machinelearning SAR/QSAR predictive optimisation

Toxicodynamics & Hazard Profile

  • Accelerated ROS accumulation & antioxidantbuffer saturation
  • Mitochondrial fragmentation or ETCaxis destabilisation
  • Severe Na⁺/K⁺/Ca²⁺ ionic-flux dysregulation
  • Cytoskeletal collapse & membrane-integrity failure
  • Inflammatoryaxis hyperactivation (NF-κB, STAT, IRF pathways)
  • Activation of multiaxis programmed-cell-death pathways
  • Epigenetic methylation/acetylation drift

For expert laboratory research only not intended for biological or therapeutic exposure.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C20H29N5O6

Molecular Weight

435.5 g/mol

CAS Number

35795-16-5

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

TRIMAZOSIN; 35795-16-5; Trimazosine; Trimazosinum; trimazosina

IUPAC/Chemical Name

(2-hydroxy-2-methylpropyl) 4-(4-amino-6,7,8-trimethoxyquinazolin-2-yl)piperazine-1-carboxylate

InChl Key

YNZXWQJZEDLQEG-UHFFFAOYSA-N

InChl Code

InChI=1S/C20H29N5O6/c1-20(2,27)11-31-19(26)25-8-6-24(7-9-25)18-22-14-12(17(21)23-18)10-13(28-3)15(29-4)16(14)30-5/h10,27H,6-9,11H2,1-5H3,(H2,21,22,23)

References

https://pubchem.ncbi.nlm.nih.gov/compound/37264;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download